Reports have documented a high expression H19 in patients with AS, where H19 inhibits vascular endothelial cell apoptosis in arteriosclerosis obliterans through regulation of the mitogen-activated protein kinase/nuclear factor kappa-B signaling pathway [8, 10]. Here, H19 is linked to arteriosclerosis obliterans.